GAMMA Investing LLC Makes New $41,000 Investment in BioLife Solutions, Inc. (NASDAQ:BLFS)

GAMMA Investing LLC purchased a new position in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 2,394 shares of the medical equipment provider’s stock, valued at approximately $41,000.

Other institutional investors have also recently made changes to their positions in the company. Nisa Investment Advisors LLC increased its holdings in shares of BioLife Solutions by 167.2% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,630 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 1,020 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in BioLife Solutions by 88.4% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 11,346 shares of the medical equipment provider’s stock worth $157,000 after acquiring an additional 5,324 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in BioLife Solutions by 8.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,622 shares of the medical equipment provider’s stock worth $216,000 after purchasing an additional 1,164 shares during the last quarter. Dark Forest Capital Management LP acquired a new stake in BioLife Solutions during the 3rd quarter worth $223,000. Finally, Illinois Municipal Retirement Fund acquired a new stake in BioLife Solutions during the 3rd quarter worth $270,000. 93.24% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group began coverage on shares of BioLife Solutions in a research report on Thursday, April 4th. They set a “buy” rating and a $22.00 price target on the stock. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $23.40.

BioLife Solutions Stock Down 0.7 %

Shares of NASDAQ:BLFS opened at $18.03 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.86 and a quick ratio of 1.83. The firm has a market capitalization of $816.76 million, a PE ratio of -11.86 and a beta of 1.69. The firm’s 50-day moving average is $17.37 and its two-hundred day moving average is $15.64. BioLife Solutions, Inc. has a 1 year low of $8.92 and a 1 year high of $24.50.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Thursday, February 29th. The medical equipment provider reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.02. The company had revenue of $32.73 million for the quarter, compared to analyst estimates of $32.70 million. BioLife Solutions had a negative net margin of 46.37% and a negative return on equity of 13.36%. Analysts predict that BioLife Solutions, Inc. will post -0.6 EPS for the current year.

Insider Buying and Selling

In other BioLife Solutions news, insider Sarah Aebersold sold 4,000 shares of the stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $17.65, for a total value of $70,600.00. Following the sale, the insider now owns 65,843 shares of the company’s stock, valued at approximately $1,162,128.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CMO Todd Berard sold 10,000 shares of BioLife Solutions stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $15.67, for a total value of $156,700.00. Following the completion of the transaction, the chief marketing officer now owns 129,644 shares in the company, valued at $2,031,521.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Sarah Aebersold sold 4,000 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $17.65, for a total transaction of $70,600.00. Following the completion of the sale, the insider now directly owns 65,843 shares in the company, valued at $1,162,128.95. The disclosure for this sale can be found here. Insiders sold 33,996 shares of company stock valued at $562,145 in the last three months. 2.70% of the stock is owned by corporate insiders.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.